Senior Director, Biosecurity Solutions

Ginkgo Bioworks is a publicly traded (NYSE: $DNA), high-growth biotechnology company based in Boston’s Seaport District, that is redesigning the living world to solve some of the globe’s growing challenges in health, energy, food, material, and more. Our mission to “make biology easier to engineer” is poised to disrupt multiple industries by leveraging our innovative data, automation, and scale capabilities in biological engineering. 
In response to the global COVID-19 pandemic, we have launched a new division: Concentric by Ginkgo. We firmly believe that testing is an essential requirement to re-open the economy as quickly and safely as possible. Concentric is the largest provider of K-12 COVID-19 testing. We currently run state-level K-12 testing programs in more than 10 states and some of the nation’s largest school districts. To date, Concentric has sequenced more than 10,000 samples from a variety of sample types, in support of public health. As we continue to scale Concentric by Ginkgo, our work is also evolving and expanding into new and exciting directions. 

Responsibilities

• Identify, develop, and grow new USG or other Government opportunities in Biosecurity in coordination with Concentrics Business Development team
• Plan and implement business development strategy for portfolio of DOD, HHS, USAID, NSC, State  and Fed Civ Government agencies 
• Build pipeline of qualified opportunities for portfolio of Fed Civ Government agencies 
• Serves as a subject-matter expert for USG-Biosecurity funding within Concentric
• Attends/speaks at industry conferences 
• Coordinates Business Development related activities with other groups and functions across the organization
• Supports proposal writing activities, including writing and reviewing content
• Travels as necessary

Minimum Requirements

• Master’s degree in a life sciences field (e.g., biotechnology, medicine, molecular biology, public health, genetics)
• Min of 5 years of USG-relevant experience (within USG, or supporting)
• Understanding of OMB and Federal Civilian contracting and decision making

Preferred Capabilities and Experience

• Ph.D. a plus 
• 12+ years experience in a OMB, EOP setting
• Demonstrated ability to build and nurture a pipeline of qualified opportunities with Government agencies
• Demonstrated ability to thoughtfully expand existing partnerships
• Passion for collaboration and significant experience in relationship-building, and ability to leverage and convert market knowledge and relationships into business opportunities 
• Motivation and ability to innovate while working towards Concentrics goals
• Excellent communication skills, emotional intelligence, and an ability to work across organizational boundaries
• Eagerness to learn quickly in a fast-paced environment and enthusiasm to be a part of Concentrics mission
• Knowledge of federal acquisition policies, processes, procedures, and contracting laws 

Note on culture: Concentric by Ginkgo is a high energy, positive and fast paced environment where new challenges and opportunities arise every day, so this opportunity is ideal for people who thrive in those kinds of environments, and for people who like lots of variety in their day. There are lots of opportunities to learn and grow. The team is motivated by doing high impact work in service to society. To get a sense of the culture at Ginkgo, read some articles in Grow by Ginkgo, the company magazine we produce, which tells the story of synthetic biology in a Ginkgo-authentic way.
To learn more about Ginkgo, check out some recent press:What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe)Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal)